Literature DB >> 24656791

RETRACTED: An ATP-competitive inhibitor modulates the allosteric function of the HER3 pseudokinase.

Peter Littlefield1, Mark M Moasser2, Natalia Jura3.   

Abstract

Human epidermal growth factor receptor 3 (HER3) is a receptor tyrosine kinase that lacks catalytic activity but is essential for cellular homeostasis due to its ability to allosterically activate EGFR and HER2. Although catalytically inactive, HER3 binds ATP tightly, hinting at a possible role of the nucleotide-binding pocket in modulating HER3 function. We report a structure of the HER3 pseudokinase bound to the ATP-competitive inhibitor bosutinib. Previously solved structures show that bosutinib can potently interact with multiple kinase domain conformations. In complex with HER3, bosutinib binds to yet another conformation, which is nearly identical to that observed in the HER3-ATP complex. Interestingly, occupation of the ATP-binding site by bosutinib improves the ability of HER3 to act as an allosteric activator of EGFR in vitro by increasing the affinity of the HER3-EGFR heterodimer in a membrane-dependent manner.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24656791      PMCID: PMC4018233          DOI: 10.1016/j.chembiol.2014.02.011

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  27 in total

1.  Heregulin reverses the oligomerization of HER3.

Authors:  R Landgraf; D Eisenberg
Journal:  Biochemistry       Date:  2000-07-25       Impact factor: 3.162

2.  Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors.

Authors:  Stephanie Blencke; Birgit Zech; Ola Engkvist; Zoltán Greff; László Orfi; Zoltán Horváth; György Kéri; Axel Ullrich; Henrik Daub
Journal:  Chem Biol       Date:  2004-05

Review 3.  Protein kinase inhibitors: insights into drug design from structure.

Authors:  Martin E M Noble; Jane A Endicott; Louise N Johnson
Journal:  Science       Date:  2004-03-19       Impact factor: 47.728

4.  Oligomers of ERBB3 have two distinct interfaces that differ in their sensitivity to disruption by heregulin.

Authors:  Kian Kani; Carmen M Warren; Catherine S Kaddis; Joseph A Loo; Ralf Landgraf
Journal:  J Biol Chem       Date:  2004-12-20       Impact factor: 5.157

5.  An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor.

Authors:  Xuewu Zhang; Jodi Gureasko; Kui Shen; Philip A Cole; John Kuriyan
Journal:  Cell       Date:  2006-06-16       Impact factor: 41.582

6.  ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.

Authors:  Jeffrey A Engelman; Pasi A Jänne; Craig Mermel; Joseph Pearlberg; Toru Mukohara; Christina Fleet; Karen Cichowski; Bruce E Johnson; Lewis C Cantley
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-24       Impact factor: 11.205

7.  Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment.

Authors:  Natalia Jura; Nicholas F Endres; Kate Engel; Sebastian Deindl; Rahul Das; Meindert H Lamers; David E Wemmer; Xuewu Zhang; John Kuriyan
Journal:  Cell       Date:  2009-06-26       Impact factor: 41.582

Review 8.  Emerging roles of pseudokinases.

Authors:  Jérôme Boudeau; Diego Miranda-Saavedra; Geoffrey J Barton; Dario R Alessi
Journal:  Trends Cell Biol       Date:  2006-08-01       Impact factor: 20.808

9.  Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3.

Authors:  Natalia V Sergina; Megan Rausch; Donghui Wang; Jimmy Blair; Byron Hann; Kevan M Shokat; Mark M Moasser
Journal:  Nature       Date:  2007-01-07       Impact factor: 49.962

10.  ATP and MO25alpha regulate the conformational state of the STRADalpha pseudokinase and activation of the LKB1 tumour suppressor.

Authors:  Elton Zeqiraj; Beatrice Maria Filippi; Simon Goldie; Iva Navratilova; Jérôme Boudeau; Maria Deak; Dario R Alessi; Daan M F van Aalten
Journal:  PLoS Biol       Date:  2009-06-09       Impact factor: 8.029

View more
  10 in total

1.  ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation.

Authors:  Henrik M Hammarén; Daniela Ungureanu; Jean Grisouard; Radek C Skoda; Stevan R Hubbard; Olli Silvennoinen
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-30       Impact factor: 11.205

2.  The Tribbles 2 (TRB2) pseudokinase binds to ATP and autophosphorylates in a metal-independent manner.

Authors:  Fiona P Bailey; Dominic P Byrne; Krishnadev Oruganty; Claire E Eyers; Christopher J Novotny; Kevan M Shokat; Natarajan Kannan; Patrick A Eyers
Journal:  Biochem J       Date:  2015-04-01       Impact factor: 3.857

3.  Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin.

Authors:  Marcia R Campbell; Hui Zhang; Shabnam Ziaee; Ana Ruiz-Saenz; Nathaniel Gulizia; Julie Oeffinger; Dhara N Amin; Deepika Ahuja; Mark M Moasser; Catherine C Park
Journal:  Breast Cancer Res Treat       Date:  2016-02-09       Impact factor: 4.872

4.  Targeting HER2 by Combination Therapies.

Authors:  Ana Ruiz-Saenz; Mark M Moasser
Journal:  J Clin Oncol       Date:  2018-01-30       Impact factor: 44.544

5.  Targeting HER3 by interfering with its Sec61-mediated cotranslational insertion into the endoplasmic reticulum.

Authors:  A Ruiz-Saenz; M Sandhu; Y Carrasco; R L Maglathlin; J Taunton; M M Moasser
Journal:  Oncogene       Date:  2015-01-26       Impact factor: 9.867

6.  Pharmacological targeting of the pseudokinase Her3.

Authors:  Ting Xie; Sang Min Lim; Kenneth D Westover; Michael E Dodge; Dalia Ercan; Scott B Ficarro; Durga Udayakumar; Deepak Gurbani; Hyun Seop Tae; Steven M Riddle; Taebo Sim; Jarrod A Marto; Pasi A Jänne; Craig M Crews; Nathanael S Gray
Journal:  Nat Chem Biol       Date:  2014-10-19       Impact factor: 15.040

7.  Flicking the molecular switch underlying MLKL-mediated necroptosis.

Authors:  Joanne M Hildebrand; Isabelle S Lucet; James M Murphy
Journal:  Mol Cell Oncol       Date:  2015-01-23

8.  Navigating into the binding pockets of the HER family protein kinases: discovery of novel EGFR inhibitor as antitumor agent.

Authors:  Wei Liu; Jin-Feng Ning; Qing-Wei Meng; Jing Hu; Yan-Bin Zhao; Chao Liu; Li Cai
Journal:  Drug Des Devel Ther       Date:  2015-07-23       Impact factor: 4.162

Review 9.  Nucleotide-binding mechanisms in pseudokinases.

Authors:  Henrik M Hammarén; Anniina T Virtanen; Olli Silvennoinen
Journal:  Biosci Rep       Date:  2015-11-20       Impact factor: 3.840

10.  Structure of Fam20A reveals a pseudokinase featuring a unique disulfide pattern and inverted ATP-binding.

Authors:  Jixin Cui; Qinyu Zhu; Hui Zhang; Michael A Cianfrocco; Andres E Leschziner; Jack E Dixon; Junyu Xiao
Journal:  Elife       Date:  2017-04-22       Impact factor: 8.140

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.